candidate vaccine (Sanofi + GSK)

The candidate vaccine being developed by Sanofi Pasteur and GSK is an S protein (baculovirus production) type of candidate vaccine. It is based on the Protein Subunit platform, which is also used for non-COVID-19 candidates, such as Influenza, and SARS-CoV. Currently, this COVID-19 candidate vaccine is in pre-clinical evaluation.

On May 17, 2021, Sanofi and GSK announced that their COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in the Phase 2 trial. A Phase 3 study is expected to start in the coming weeks.